N Engl J Med 379 (2): 111-121, 2018.[PUBMED Abstract] Sparano JA, Gray RJ, Makower DF, et al.: Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med 373 (21): 2005-14, 2015.[PUBMED Abstract] Sparano JA, Gray RJ, Ravdin PM, et al.: Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med 380 (25): 2395-2405, 2019.[PUBMED Abstract] Cardoso F, van't Veer LJ, Bogaerts J, et al.: 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med 375 (8): 717-29, 2016.[PUBMED Abstract] Kalinsky K, Barlow WE, Meric-Bernstam F, et al.: Abstract GS3-00: first results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder).